Home › Endometrial Cancer › Michigan › Lansing
Endometrial Cancer clinical trials in Lansing, MI
4 studies for Endometrial Cancer are looking for participants at sites in and around Lansing (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RecruitingPhase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Michigan Health - Sparrow Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Lansing
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY53 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN37 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- San Antonio, TX27 studies
- Columbus, OH26 studies
- Chicago, IL26 studies
- Queens, NY26 studies
Other studies in Lansing
- Lung Cancer11 studies
- Breast Cancer10 studies
- Prostate Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Cancer (all types)7 studies
- Disorders of Excessive Somnolence5 studies
- Laryngeal Cancer5 studies
- Bladder Cancer5 studies
- Sleep Disorders4 studies
- Colorectal Cancer4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Hypopharyngeal Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.